Published 2023
| Version v1
Poster
Open
Differentially Expressed Genes In Recurrent Classical Hodgkin Lymphoma And Exploring The Potential For Repurposed Drugs
Authors/Creators
- 1. Precision Medicine Lab (CECOS RMI)
- 2. Institute of Integrative Biosciences, CECOS University
Description
Lymphoma is a general term for cancer that starts in the lymph system (Mugnaini EN et al., 2016). There are two categories of lymphoma (Radiol Am et al., 2008): Hodgkin’s lymphoma and Non-Hodgkin’s lymphoma.
The American Joint Committee on Cancer (AJCC) recognizes two major categories of Hodgkin lymphoma (Matasar et al., 2008): 1) classic Hodgkin lymphoma (95%) and 2) nodular lymphocyte-predominant Hodgkin lymphoma (5%). Although its general prognosis is favorable, 10%–30% of patients with classic Hodgkin lymphoma (cHL) will ultimately develop relapsed or refractory disease (Ansell SM et al., 2015). A stem cell transplant complemented with high-dose chemotherapy is the main treatment used for relapsed cHL (Potre O et al., 2021).
Files
Ahad Ali 2023.pdf
Files
(1.0 MB)
| Name | Size | Download all |
|---|---|---|
|
md5:3aefdfb6274f4cf35684a0a47c79b818
|
1.0 MB | Preview Download |
Additional details
References
- Mugnaini, E. N., & Ghosh, N. "Lymphoma," Prim Care, 2016 Dec; 43(4): 661-675. doi: 10.1016/j.pop.2016.07.012. PMID: 27866584
- Matasar, M. J., & Zelenetz, A. D. "Overview of lymphoma diagnosis and management," Radiol Clin North Am, 2008 Mar; 46(2): 175-198, vii. doi: 10.1016/j.rcl.2008.03.005. PMID: 18619375.
- Ansell, S. M. "Hodgkin Lymphoma: Diagnosis and Treatment," Mayo Clin Proc, 2015 Nov; 90(11): 1574-1583. doi: 10.1016/j.mayocp.2015.07.005. PMID: 26541251.
- Potre, O., Pescaru, M., Sima, A., Ionita, I., Tudor, R., Borsi, E., Samfireag, M., & Potre, C. "Evaluation of the Relapse Risk and Survival Rate in Patients with Hodgkin Lymphoma: A Monocentric Experience," Medicina (Kaunas), 2021 Sep 27; 57(10): 1026. doi: 10.3390/medicina57101026. PMID: 34684063; PMCID: PMC8540813.